Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
521-540 of 1,738 trials

Ulcerative Colitis: Eltrekibart Treatment Study

We are studying whether eltrekibart can help adults with moderately to severely active ulcerative colitis achieve remission. This trial compares the effects of eltrekibart to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Triple-Negative Breast Cancer: 68Ga-FAPI-46 PET/CT Imaging Study

We are investigating whether a new imaging method can predict how well early-stage high-risk triple-negative breast cancer patients respond to chemotherapy and immunotherapy. This may help tailor treatments more effectively.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyOtolaryngology

Severe Systemic Lupus Erythematosus: Belimumab and Rituximab Study

We are investigating whether combining belimumab with rituximab can improve treatment outcomes for people with severe systemic lupus erythematosus. This study will compare this combination to standard treatments to see if it better reduces harmful autoantibodies and improves overall health.

Systemic Lupus Erythematosus>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Multiple Sclerosis: Ifenprodil Study

We are investigating whether Ifenprodil can help repair nerve damage in people with Multiple Sclerosis. This study aims to see if it may improve symptoms and overall function.

Multiple Sclerosis>2 yearsSafety phase (I)Efficacy phase (II)Neurology

Advanced Triple-Negative Breast Cancer: TONIC-3 Trial

We are studying new immunotherapy strategies for patients with advanced triple-negative breast cancer. The goal is to see if these treatments are safe and effective, and to learn more about how tumors respond to them.

Metastatic Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Self-Administration of Elranatamab for Multiple Myeloma

We are exploring whether patients with multiple myeloma can safely administer Elranatamab at home. The study will assess the feasibility, safety, and impact on quality of life for both patients and their caregivers.

Multiple Myeloma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Acute Myeloid Leukemia: Gilteritinib with Venetoclax and Azacitidine

We are studying a combination of three medications for patients with newly diagnosed acute myeloid leukemia and FLT3 mutations who cannot receive intensive treatment. The goal is to find the best dose that is safe and effective.

Acute Myeloid LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Advanced Cancer: Targeted Drug Study

We are investigating whether approved cancer drugs can help patients with advanced cancer who have specific genetic markers. This study aims to improve treatment options by using these drugs in new ways.

CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Esophageal Strictures: Budesonide Tablets

We are studying whether budesonide tablets can help prevent esophageal strictures in adults after cancer surgery. This trial compares two doses of the medication to a placebo to assess effectiveness and safety.

Oesophageal Cancer and Related Conditions>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesGastroenterologyOncology

Isatuximab for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

We are studying whether Isatuximab can safely help adults with relapsed or refractory T-cell acute lymphoblastic leukemia achieve remission. This trial looks at its effects alone and with other chemotherapy drugs.

T-cell Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Ovarian Cancer: Raludotatug Deruxtecan Study

We are studying a new drug for patients with platinum-resistant, high-grade ovarian cancer. The goal is to see if it works better than current treatment options.

Ovarian and Related Cancers>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: First-in-Human Study of DS-3939a

We are testing a new treatment called DS-3939a to see if it is safe and effective for people with advanced solid tumors. This study aims to understand how well it works and its effects on tumor tissue.

Metastatic Solid TumorAdvanced Solid TumorSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Colchicine for Angina in Microvascular Disease

We are studying whether colchicine can improve blood flow and reduce symptoms in patients with angina caused by coronary microvascular dysfunction. This research may help us understand how to better treat this condition.

Cardiovascular Disease (CMD)>2 yearsEfficacy phase (II)Standard MedicinesCardiology

DZR123 for Advanced Solid Tumors and Lymphomas

We are studying a new treatment called DZR123 for patients with advanced solid tumors and lymphomas. The trial will help us understand its safety and how well it works alone and with another medication.

Advanced Solid Tumors and Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Levosimendan for Heart Support During ECMO Weaning

We are studying whether Levosimendan can improve heart function in patients being weaned from ECMO. This may help reduce complications and support recovery during this critical period.

Cardiogenic ShockEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Postmenopausal Bone Health: Everolimus and Exercise Study

We are investigating whether everolimus, exercise, or both can improve bone formation in healthy postmenopausal women. This study aims to help prevent bone loss and support skeletal health.

Healthy Participants3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyInternal MedicineOrthopedics and Traumatology

ROS1-Positive Lung Cancer: REPotrectinib Study

We are testing a new treatment for patients with ROS1-positive non-small cell lung cancer and active brain metastasis. The study aims to see how well it works in shrinking brain tumors and to assess its safety.

ROS1-positive Non-Small Cell Lung Cancer with Brain Metastasis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurologyOncology

Anakinra for Persistent Respiratory Symptoms After COVID-19

We are studying whether anakinra can help patients with ongoing respiratory issues after COVID-19 improve their symptoms and immune function. This trial is for those experiencing long-term effects of the virus.

Post-Acute COVID Syndrome≤3 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesInfectious DiseasesInternal MedicinePulmonology

Bipolar Depression: Esketamine Nasal Spray

We are studying the safety and effectiveness of esketamine nasal spray for people with treatment-resistant bipolar depression. This trial aims to gather important information that could lead to future studies.

Bipolar Disorder - Depressive Episode≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPsychiatry

Chronic Myeloid Leukemia: Asciminib for Kids

We are studying the safety and appropriate dose of asciminib in children with chronic myeloid leukemia. This research aims to ensure the medication is safe and effective for young patients who have already tried other treatments.

Philadelphia Positive Chronic Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics